Day One Biopharmaceuticals, Inc. (DAWN) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Day One Biopharmaceuticals, Inc. (DAWN) Earnings Overview
As of June 21, 2026, Day One Biopharmaceuticals, Inc. (DAWN) reported trailing twelve-month net income of -$107M, reflecting -2.0% year-over-year growth. The company earned $-1.04 per diluted share over the past four quarters, with a net profit margin of -67.8%.
Looking at the long-term picture, DAWN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2019.
Day One Biopharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KURA (-$295M net income, -412.9% margin), TGTX ($462M net income, 72.6% margin), IMVT (-$506M net income), DAWN has outperformed on profitability metrics. Compare DAWN vs KURA →
DAWN Earnings vs Peers
Earnings metrics vs comparable public companies
DAWN Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$107M | -12.4% | -$128M | $-1.04 | -67.8% | -80.8% |
| 2024 | -$95M | +49.5% | -$217M | $-1.02 | -72.8% | -165.7% |
| 2023 | -$189M | -32.9% | -$206M | $-2.37 | - | - |
| 2022 | -$142M | -101.3% | -$147M | $-2.02 | - | - |
| 2021 | -$71M | -74.4% | -$73M | $-1.14 | - | - |
| 2020 | -$41M | -220.6% | -$14M | $-0.65 | - | - |
| 2019 | -$13M | - | -$15M | $-0.24 | - | - |
Download Data
Export DAWN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DAWN — Frequently Asked Questions
Quick answers to the most common questions about buying DAWN stock.
What is DAWN earnings per share (EPS)?
DAWN trailing twelve-month (TTM) diluted EPS is $-1.04, reflecting -2.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Day One Biopharmaceuticals, Inc.'s net income?
Day One Biopharmaceuticals, Inc. (DAWN) trailing twelve-month net income is $-107M as of 2025. Earnings declined -2.0% year-over-year.
Is DAWN profitable?
DAWN is not currently profitable on a TTM basis, reporting a net loss of $-107M. Net margin is -67.8%. Investors should monitor for a return to profitability.
What is DAWN's earnings growth rate?
DAWN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are DAWN's profit margins?
Day One Biopharmaceuticals, Inc. net profit margin is -67.8%, operating margin is -80.8%, and gross margin is +89.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -22.7%.
Is DAWN growing earnings?
DAWN earnings growth is slowing. Current YoY EPS growth of -2.0% trails the 5-year CAGR of N/A. TTM net income is $-107M.
What was DAWN's best earnings year?
Day One Biopharmaceuticals, Inc.'s highest annual net income on record is $-13M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were DAWN's earnings last quarter?
DAWN's most recent reported quarter was Q4 2025. Net income was $-21M with diluted EPS of $-0.21. For a full breakdown of all quarters, see the quarterly earnings table on this page.